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Researchers early on recognized that chronic
beryllium disease (CBD) occurred after both
high and low levels of exposure and hypothe-
sized that the disease was immunologically
mediated (Sterner and Eisenbud 1951).
Subsequent work has confirmed the impor-
tance of cellular immunity to beryllium in the
pathogenesis of CBD (Rossman 2001). The
factors that determine why some individuals
develop cellular immunity to beryllium while
others do not still need to be elucidated.
Medical screenings of beryllium-exposed
workers consistently demonstrate that a larger
percentage of individuals will have a positive
blood lymphocyte proliferation test to beryl-
lium (become sensitized) than will be diag-
nosed with CBD (sensitization and granuloma
in lung parenchyma) (Henneberger et al.
2001; Kelleher et al. 2001; Kreiss et al. 1993a;
Stange et al. 2001). It is not known what pro-
portion of individuals who are sensitized to
beryllium will progress to develop CBD.
Furthermore, there is a varied clinical presen-
tation of patients with CBD and variability in
its progression (Newman et al. 1996;
Rossman et al. 1999).
The current occupational air standard for
beryllium, ﬁrst proposed in 1951, was based
on the toxicity of other metals such as arsenic,
lead, and mercury and modified to reflect
beryllium’s lower atomic weight and concern
about its greater toxicity (Eisenbud 1982).
Epidemiologic health outcome and exposure
studies were not used to develop the initial
time-weighted average permissible exposure
level of 2 µg/m3. Fifty years later, this remains
the current air level that Occupational Safety
and Health Administration (OSHA) enforces
in the workplace.
Recent studies looking at beryllium disease
and exposure have either used a surrogate of
exposure (i.e., months of exposure, percent
exposed to unﬁred beryllium oxide) or calcu-
lated exposure metrics and found increased
disease with some parameters of increased
exposure (Henneberger et al. 2001; Kelleher
et al. 2001; Kreiss et al. 1993b, 1997; Viet
et al. 2000). One study found an exposure–
response relationship for sensitization with
CBD but not for sensitization without CBD
(Viet et al. 2000). Other work has addressed
the possibility of particle size (McCawley et al.
2001), skin absorption (Tinkel et al. 2003),
and/or genetic susceptibility (Saltini et al.
2001) as important factors that confound a
straightforward exposure–response relationship.
We investigated possible exposure–
response relationships separately for various
measures of exposure, including mean, peak,
and cumulative metrics and differing chemi-
cal and physical forms for the development of
beryllium sensitization and for the develop-
ment of CBD.
We have also assessed whether the current
OSHA (2005) and Department of Energy
(DOE 1999) permissible levels were protec-
tive against the development of CBD and
sensitization.
Materials and Methods
The cohort was composed of workers from a
beryllium production facility in eastern
Pennsylvania, which operated from 1957 to
1978. The names of former workers with at
least 2 days of work up to 31 December 1969
who had previously been identiﬁed from per-
sonnel records and matched with Social
Security Administration Form 941 records by
the National Institute for Occupational Safety
and Health (NIOSH), as part of a seven-com-
pany mortality study, were obtained from
NIOSH (Ward et al. 1992). The last owner of
the facility provided the names of workers,
social security numbers, demographic infor-
mation, and the last known address of all indi-
viduals who began work from 1 January 1970
until the plant closed in 1978.
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We conducted a medical screening for beryllium disease of 577 former workers from a beryllium
processing facility. The screening included a medical and work history questionnaire, a chest radi-
ograph, and blood lymphocyte proliferation testing for beryllium. A task exposure and a job expo-
sure matrix were constructed to examine the association between exposure to beryllium and the
development of beryllium disease. More than 90% of the cohort completed the questionnaire, and
74% completed the blood and radiograph component of the screening. Forty-four (7.6%) individ-
uals had deﬁnite or probable chronic beryllium disease (CBD), and another 40 (7.0%) were sensi-
tized to beryllium. The prevalence of CBD and sensitization in our cohort was greater than the
prevalence reported in studies of other beryllium-exposed cohorts. Various exposure measures
evaluated included duration; ﬁrst decade worked; last decade worked; cumulative, mean, and high-
est job; and highest task exposure to beryllium (to both soluble and nonsoluble forms). Soluble
cumulative and mean exposure levels were lower in individuals with CBD. Sensitized individuals
had shorter duration of exposure, began work later, last worked longer ago, and had lower cumu-
lative and peak exposures and lower nonsoluble cumulative and mean exposures. A possible
explanation for the exposure–response findings of our study may be an interaction between
genetic predisposition and a decreased permanence of soluble beryllium in the body. Both CBD
and sensitization occurred in former workers whose mean daily working lifetime average expo-
sures were lower than the current allowable Occupational Safety and Health Administration
workplace air level of 2 µg/m3 and the Department of Energy guideline of 0.2 µg/m3. Key words:
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http://dx.doi.org/ [Online 26 May 2005]Because this study was a cooperative
effort with NIOSH, addresses from the last
income tax filing of members of the cohort
were obtained by NIOSH from the Internal
Revenue Service. NIOSH had previously
ascertained the vital status of the cohort as of
31 December 1988 using the Social Security
Administration, the Internal Revenue Service,
post office cards mailed to the last known
address, the Department of Veterans Affairs,
the Health Care Finance Administration, and
the National Death Index (Ward et al.
1992).
We mailed the initial invitation to partici-
pate in the medical screening program to the
last known address of all members of the cohort
not known to be deceased as of 31 December
1988. The mailing included a cover letter about
the study, a fact sheet about beryllium, a one-
page two-sided questionnaire, and a postage-
paid envelope. The questionnaire requested
demographic information and had questions
about previous lung disease, smoking history,
and work history at the beryllium facility.
We attempted to contact everyone who
did not return the questionnaire. This
included multiple phone contacts or actual
visits to the person’s home if telephone con-
tact was unsuccessful. Internet address searches
using search engines such as Yahoo! and
Netscape were performed to locate current
mailing addresses of individuals with returned
mailings. In addition, we used the Social
Security Death Index (Ancestry.com 2005) to
help determine vital status of individuals.
Local staff in the two communities not only
made visits to last known addresses but also
asked the long-term workers to assist in identi-
fying individuals who could not be located.
All individuals located, whether or not
they participated in the medical screening or
completed a questionnaire, received a subse-
quent mailing summarizing the results of the
screening and notiﬁcation of federal legislation
passed in the fall of 2000 that provided com-
pensation for workers with CBD and coverage
for medical costs for follow-up of workers
with beryllium sensitization from this facility.
All individuals located had the opportunity
to have a blood lymphocyte proliferation test
for beryllium (BeLPT), a posterior–anterior
chest radiograph, and simple spirometry.
Before the testing, we obtained consent to con-
duct testing from the individual. In addition,
each participant completed a questionnaire on
other work exposures that might contribute to
respiratory deficiencies. This included other
possible sources of beryllium exposure as well
as exposure to asbestos, coal, and silica.
Medical testing was performed at two pri-
mary sites in the community in eastern
Pennsylvania. For individuals who had moved
to other parts of the country, medical testing
was performed in a location convenient to the
individual (i.e., personal physician, local medi-
cal centers, etc.).
Blood was collected Monday through
Thursday and shipped for next morning
delivery. All blood was processed the next day
and analyzed. All BeLPT was performed at
the University of Pennsylvania. Any individ-
ual with a positive BeLPT test was offered a
repeat test. If an individual’s results were
negative on the repeat test, then the individ-
ual was offered the opportunity to repeat the
blood test 1 year later.
A panel of three “B” readers interpreted all
chest radiographs. One B reader was a radiolo-
gist (J.A.), one a pulmonologist (J.E.P.), and
one an internist and occupational medicine
physician (K.R.). At least two B readers had to
classify a radiograph with ≥ 1/0 profusion in
order for a radiograph to be classiﬁed as posi-
tive for parenchymal disease.
Any individual who had two positive
BeLPTs and/or a consensus chest radiograph
reading of ≥ 1/0 for profusion was referred to
the University of Pennsylvania for follow-up
testing, which consisted of a posterior–anterior
chest radiograph, a BeLPT, an electrocardio-
gram, a complete medical history including
respiratory symptoms using a standardized
collection instrument, and bronchoscopy with
both bronchial biopsy and lymphocyte testing
of lavage fluid for beryllium. All broncho-
scopies were performed by a single pulmo-
nologist (M.R.).
Whether or not an individual had CBD
or beryllium sensitization was decided by con-
sensus by the internist/occupational physician
(K.R.) and pulmonologist (M.R.). Table 1
outlines the criteria used to categorize the
medical testing results. However, only indi-
viduals who had bronchoscopy were used in
the analysis describing the predictive power of
radiographs or BeLPT.
All individuals received a letter with the
results of their initial screening and, where
applicable, a letter with the results of the 
follow-up testing. The Human Subject Review
Boards of Emory University, Michigan State
University, the University of Cincinnati, and
the University of Pennsylvania approved this
study.
Through discussions with long-term pro-
duction and management employees, we iden-
tified major changes in the process and
engineering/work practice controls. Trends in
the exposures over time were evaluated in rela-
tion to dates of process changes and visually
from plots of the data to identify other time
points at which exposure measurements indi-
cated a change in conditions.
Exposure had been monitored at the facility
using a method that combined the concentra-
tion at each task performed by a worker,
weighted by the duration in the shift of that
task; the products of concentration and dura-
tion at all tasks performed as part of a job were
summed and divided by the duration to the
shift. This final value was called the daily
weighted average (DWA) exposure. Data accu-
mulated over the operating history of the plant
were identiﬁed and computerized. Using this
information, a task exposure matrix (TEM) and
a job exposure matrix (JEM) were constructed
(Chen 2001). Task-related exposure measure-
ments were available for two time periods,
1957–1962 and 1971–1976. Because the data
most closely followed a log-normal distribution,
the geometric mean was calculated for each
task-year combination. For years with no mea-
surements, we estimated exposures by interpo-
lating between the previous and subsequent
values. For example, if measurements were
available for 1957, 1958, and 1959 but not for
1960, the 1959 value was entered into the
TEM. The plant history was used to develop a
strategy for imputing values from 1963 to
1971. We used the mean of task estimates for
1962 and 1971 for the period 1963–1969;
because of the engineering changes in 1970, the
1971 values were used for 1970. Estimates for
1976 were used for the remaining years of
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Table 1. Criteria for beryllium disease categories.
Bronchial Biopsy
Disease category lavage granuloma Chest radiograph Blood LPT Spirometry
CBD + BAL LPT Positive
Not done Positive Two + LPTs
Not done Positive Upper lobe ﬁbrosis
Probable CBD + BAL LPT Upper lobe ﬁbrosis
Not done Upper lobe ﬁbrosis Two + LPTs
Possible CBD Not done Upper lobe ﬁbrosis – LPT
Not done Upper lobe ﬁbrosis Single + LPT
and no retest
Sensitization – BAL LPT Negative Normal Two + LPTs Normal
+ BAL LPT Negative Normal Normal
Not done Lower or midlobe Two + LPTs Normal
ﬁbrosis or normal
Possible sensitization Single + LPT and
no retest or – LPT
retests
Abbreviations: –, negative; +, positive; BAL, bronchoalveolar lavage; LPT, lymphocyte proliferation test.plant operation, based on employee interviews.
For tasks never measured, the task in the same
work area most similar to the unmeasured task
was identiﬁed with the assistance of long-term
employees; the exposure value for the mea-
sured task was entered into the TEM for the
unmeasured task.
We completed the JEM by ﬁrst calculating
the geometric mean exposure for each year in
which at least one DWA measurement was
available. Exposure estimates for job–year com-
binations without measurements were esti-
mated based on the plant history of engineering
changes. In the absence of information showing
production or control technology changes in
years before or after measurement data, the
measurements were assumed valid and
extended to the empty cells in the JEM. Where
increases or decreases in exposure were justiﬁed
from the plant history, we used analysis of vari-
ance (ANOVA) to evaluate the signiﬁcance of
the change in exposure. Where statistically sig-
niﬁcant changes were identiﬁed, the new value
was entered into the cell of the JEM.
For 39 of the 130 job titles, no measure-
ments were available for the job in any year.
For each of these jobs, we used information
from the long-term workers to identify the
job with tasks most similar to it with mea-
surements. The time–activity pattern needed
for the evaluation of exposure was developed
and used to calculate a DWA estimate of
exposure using data in the TEM.
The values were reviewed by a group of
long-term employees who represented experi-
ence in all production areas of the facility,
maintenance, and management. They were
speciﬁcally asked to review the relative expo-
sure values for production areas. For example,
the exposure estimated for the fluoride fur-
nace operator is slightly higher than the
helper; this was confirmed to be correct
because the helper stood away from the
furnace and supplied materials to the perime-
ter only. The involvement of the group of
long-term employees provided added confi-
dence in our derived estimates.
The JEM and TEM were linked through
the listing of the tasks in each job taken from
the DWA calculation sheets. For jobs never
sampled, the association was through the
time–activity information developed with the
help of long-term employees and, ﬁnally, put
into DWA format.
For every job title in the JEM, the chemi-
cal and physical form of the exposure was
listed. Chemical forms included beryl ore,
beryllium metal, beryllium ﬂuoride, beryllium
hydroxide, and beryllium oxide; physical
forms included dust, fume, or mixed (dust
and fume). Individuals from the facility were
assigned, based on jobs worked, the number of
months exposed to three different chemical
forms: nonsoluble beryllium compounds
(beryllium metal and oxide), soluble beryllium
compounds (beryllium ﬂuoride and hydroxide),
and mixed chemical forms. Individuals were
similarly assigned to the number of months
exposed to the three physical forms: dust (beryl-
lium metal, hydroxide, or oxide), fume (beryl-
lium fluoride), and mixed (mixed dust and
fume). This allowed us to evaluate any differ-
ences in response due to very small particle size
(fume) or larger particle size (dust or mixed).
We used chi-square tests to compare the
groups (deﬁnite or probable disease vs. sensi-
tized vs. no disease) with respect to discrete
outcomes. ANOVA was used to compare the
groups with respect to continuous outcomes
(age, cumulative, mean, and peak exposure
levels). For the three disease outcome group
comparisons, a screening p-value was set at
0.25, below which the pairwise comparisons
between groups (definite or probable disease
vs. no disease, deﬁnite or probable disease vs.
sensitized, sensitized vs. no disease) were 
further investigated. For the discrete out-
comes, further chi-square tests were per-
formed on the resulting 2 × k tables. For the
continuous outcomes, the linear contrasts for
these pairwise comparisons were examined in
order to control for multiple comparisons.
For ease of presentation, we also used two-
sample t-tests to examine pairwise compari-
sons of the groups. These parametric tests
were followed by the Wilcoxon rank-sum test,
a nonparametric test used to ameliorate the
effects of violations of the assumptions for the
parametric tests (e.g., normal distribution).
We further explored exposure–response
relationships with logistic regression analysis
after adjustment for potential confounders
(smoking, age, other beryllium exposure). In
addition to an analysis where only cases with
complete information were included, an analy-
sis was carried out after multiple imputations
(Rubin 1987) of cumulative and mean expo-
sure values (missing on 65 of 574 individuals).
p-Values are presented as calculated. All
analyses were performed using SAS statistical
software (version 9.1; SAS Institute, Cary,
NC). The results of the spirometry testing are
not reported in this article.
Results
A total of 1,351 individuals were identiﬁed to
have worked at this facility. A summary of the
participation rate for this facility is shown in
Table 2. Approximately one-fourth (24.4%)
of the cohort died before the medical screen-
ing began, and another 10.8% could not be
located. Among the 875 individuals located,
160 (11.8%) indicated either that they had
worked for the company that owned the facil-
ity but at a different location, or that they had
completed a job application and underwent a
pre-employment physical for work at the
facility but had either not been hired or had
decided not to accept a job at that plant.
Of the remaining 715 former employees,
the participation rate was 63.9% (457 of 715)
for completion of all components of the med-
ical screening and 91.3% (653 of 715) for com-
pletion of the questionnaire only. Five hundred
twenty-eight individuals (73.8%) completed at
least the blood and chest radiograph compo-
nent. Reasons members of the cohort gave for
not participating included that the individual
a) had only worked for a short time; b) felt he
or she was too old and that testing would not
matter; c) did not have any health problems;
d) did not want to jeopardize his or her current
health insurance, especially with no compensa-
tion available (at the time the individual was
contacted); and e) felt there was no effective
treatment for beryllium disease.
Table 3 compares the demographics of
medical screening participants with nonpartici-
pants. Medical screening took place from the
Rosenman et al.
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Unable to locate 146 (10.8)
Contacted 875
Denied ever working at facility 160 (11.8)
Potential participants 715
Medical testing 653 (91.3)
Questionnaire only 79
Questionnaire and blood 22
Questionnaire and chest radiograph 6
Questionnaire, chest radiograph, and blood 71
Questionnaire, chest radiograph, and PFTs 12
Questionnaire, PFTs, and blood 6
All components (questionnaire, 
chest radiograph, blood, and PFTs) 457
Refusals 62 (8.7)
PFT, pulmonary function test.
Table 3. Demographics of medical screening participants versus those who completed questionnaire only.a
Completed Medical screening
Characteristic questionnaire onlyb participantsc
Birth year (mean ± SE) 1936 ± 1.18 1935 ± 0.44
Male sex (%) 91.8 90.8
White race (%) 100.0 99.8
Duration (no.) of years worked (mean ± SE) 5.2 ± 0.85 8.5 ± 0.40*
Last year worked (mean ± SE) 1969 ± 0.89 1971 ± 0.32*
aSixty-two individuals who refused to complete questionnaire and medical screening are not included. bIncludes 79 indi-
viduals who completed only the questionnaire. cIncludes 574 individuals who completed questionnaires and some part of
medical screening. *p < 0.05.fall of 1996 through the summer of 2001.
Participants were on average the same age as
the nonparticipants, the same sex and race, last
worked in a more recent year, and worked on
the average 3.3 years longer. Participants were
mainly male (91%), and almost all white.
Seventy percent had ever smoked cigarettes.
Among the 577 individuals that were
tested for beryllium, 110 were referred for fol-
low-up testing at the Hospital of the
University of Pennsylvania (Table 4). In addi-
tion to the 110 referred, 9 individuals from
the facility had previously been diagnosed at
the University of Pennsylvania with CBD. All
577 individuals, including the 9 previously
diagnosed with CBD, were categorized per the
criteria in Table 1. The results of this classiﬁ-
cation are shown in Table 5. Of the cohort,
7.6% (44) had probable or definite CBD,
2.1% (12) had possible CBD, 6.9% (40) were
sensitized to beryllium, and 4.0% (23) were
possibly sensitized.
Table 6 shows the predictive power of
having unrecognized CBD documented by
bronchoscopy based on the results of the
screening tests performed. Having two posi-
tive BeLPTs and scarring on the chest radio-
graph, involving either all zones or the lower
zones only, had the highest predictive value
for the development of CBD (100%). In
descending order for the other combination of
tests, the predictive values for CBD were scar-
ring on the radiograph in all zones with nega-
tive BeLPT (75%), positive BeLPT (48.3%),
scarring in the upper zones with negative
BeLPT (40%), and scarring on the chest
radiograph just in the lower zones (7.7%).
There were 33 cases of definite/probable
CBD among production workers, 5 among
clerical/office workers, 3 in engineers, 1 in a
supervisor/inspector, 1 in a laboratory worker,
and 1 in an industrial hygiene technician.
There were 27 cases of sensitization among
production workers, 10 among clerical/ofﬁce
workers, 2 among engineers, and 1 in a nurse.
Table 7 shows the occurrence of definite
and probable CBD and sensitization by first
decade worked, last decade worked, and dura-
tion of years worked. The mean year of first
exposure for deﬁnite/probable CBD was 1963,
for sensitized cases it was 1965, and for the
normal group it was 1964. Further, the mean
year last exposed for deﬁnite/probable, sensi-
tized, and normal individuals was 1973, 1968,
and 1971, respectively. The mean duration of
exposure for deﬁnite/probable, sensitized, and
normal individuals was 9.4 years, 2.7 years,
and 8.7 years, respectively.
Tables 8–12 show the occurrence of deﬁ-
nite and probable CBD and sensitization by
the peak, average, and cumulative exposure
metric, by chemical and physical form of
beryllium and the OSHA (2005) standard of
2 µg/m3 and the DOE (1999) standard of
0.2 µg/m3. Individuals who were sensitized
had a lower total cumulative and peak expo-
sure (Table 8), lower nonsoluble cumulative
and average exposure (Table 11), and lower
dust and mixed exposure (Table 10).
Individuals with CBD had a lower soluble
(Table 9) and fume exposure (Table 10). The
mean beryllium exposure levels for the DWA
categories in Table 11 were 0, 1.23, and
8.95 µg/m3, respectively and in Table 12 were
0.14, 1.19, and 4.76 µg/m3, respectively.
Discussion
The prevalence of CBD and sensitization to
beryllium in former workers at this beryllium
production facility in eastern Pennsylvania was
high: 7.6% with CBD, 6.9% with sensitiza-
tion, 2.1% with possible CBD, and 4.0% with
possible sensitization. This facility operated
from 1957 to 1978. Representative exposure
estimates for tasks ranged from 0.9 to
84.0 µg/m3 in the 1960s, although most time-
weighted averages were below the OSHA
(2005) standard of 2 µg/m3, ranging from 1.1
to 2.5 µg/m3. Exposure estimates in the 1970s
were lower, with representative tasks ranging
from 0.5 to 16.7 µg/m3 and time-weighted
averages ranging from 0.7 to 3.5 µg/m3.
The 14.5% prevalence of CBD and sensiti-
zation in the cohort we studied contrasts with
overall prevalence reports of 3.3% among
nuclear workers from Rocky Flats (Stange et al.
2001), 1.8–5.9% from beryllium ceramics
Beryllium exposure–response study 
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Table 5. Disease categorization of medical test
results (n = 577).
Disease category No. (%)
Deﬁnite CBD 32 (5.5)
Probable CBD 12 (2.1)
Possible CBD 12 (2.1)
Sensitized 40 (6.9)
Possibly sensitized 23 (4.7)
No CBD and/or sensitization 458 (79.4)
Table 6. Predictive power of having unrecognized
CBD documented by bronchoscopy based on





Two positive BeLPTs 29 14 (48.3)
Chest radiograph 22 6 (27.3)
Profusion > 1/0 at least two
B readers
All zones 4 3 (75.0)
Upper zones only 5 2 (40.0)
Lower zones only 13 1 (7.7)
Blood and chest radiographa 5 5 (100.0)
All zones 3 3 (100.0)
Upper zones only 0 NA
Lower zones only 2 2 (100.0)
NA, not applicable.
aMet criteria for blood and chest radiograph referral. 
Table 7. Development of deﬁnite/probable CBD and sensitization by decade of ﬁrst and last exposure and duration of exposure.
Decade of ﬁrst exposure [No. (%)] Decade of last exposure [No. (%)] Duration of exposure (years) [No. (%)]
Disease outcome 1950s 1960s 1970s 1950s 1960s 1970s 1980s < 1 1 to < 5 5 to < 15 ≥ 15
Deﬁnite/probable CBD 14 (34) 17 (41) 10 (24) 3 (8) 8 (21) 22 (56) 6 (15) 10 (24) 8 (20) 11 (27) 12 (29)
Sensitization 7 (18) 22 (56) 10 (25) 1 (3) 20 (57) 14 (40) 0 (—) 9 (23) 19 (49) 9 (23) 2 (5)
Normal 112 (27) 222 (54) 75 (18) 26 (7) 126 (33) 177 (46) 58 (15) 70 (17) 136 (33) 107 (26) 99 (24)
For the decade of ﬁrst exposure, p = 0.03 for sensitization vs. normal. For the decade of last exposure, p = 0.03 for sensitization vs. deﬁnite/probable and p = 0.008 for sensitization vs. nor-
mal. For the duration of exposure, p = 0.008 for deﬁnite/probable vs. sensitization and p = 0.03 for sensitization vs. normal.
Table 8. Development of deﬁnite/probable CBD and sensitization by average cumulative, average mean, and peak exposure (± SE).
No. of Mean cumulative exposure Mean exposure Mean average exposure Mean peak exposure
Disease outcome individuals (µg-year/m3) (days) (µg/m3) (µg/m3)
Deﬁnite/probable CBD 40 181 ± 29 3,483 ± 550 8.7 ± 0.8 81 ± 14
Sensitization 37 100a ± 23 1,934b ± 55 7.1 ± 0.9 53c ±1 4
Normal 377 209 ± 16 3,359 ± 176 8.3 ± 0.3 87 ± 13
ap = 0. 03 for sensitization vs. deﬁnite/probable, and p = 0. 0003 for sensitization vs. normal. bp = 0.047 for sensitization vs. deﬁnite/probable, and p = 0.02 for sensitization vs. normal. cp =
0. 01 for sensitization vs. normal.
Table 4. Reason for referral for follow-up testing.
No. (%)
Blood
Two positive BeLPTs 53 (9.2)
Chest radiograph
Profusion > 1/0 per at least two B readers 50 (8.7)
Blood and chest radiographa 7 (1.2)
Total referred 110b (19.1)
aMet criteria for both blood and chest radiograph referral.
bNine (1.6%) additional individuals in the cohort met the
study’s criteria for CBD based on testing performed before
the study’s medical screening.manufacturing (Kreiss et al. 1993b, 1996), and
4.6% from a beryllium production facility
(Kreiss et al. 1997). Our overall prevalence is
similar to the prevalence reports for more
highly exposed subgroups from these studies,
such as machinists (Kreiss et al. 1996). Our
higher overall prevalence rate reﬂects both the
level and the widespread exposure to beryllium
in the facility we studied, where 11 deﬁnite/
probable cases occurred among nonproduc-
tion workers such as clerical, supervisory, and
engineering staff and 13 sensitization cases
occurred in clerical/office personnel. Our
mean and range of cumulative exposure,
which was 199.25 µg-year/m3 (0.0–3970.61
µg-year/m3, are appreciably higher than esti-
mates reported in other studies: 6.09
µg-year/m3 (0.15–10.64 µg-year/m3) (Kelleher
et al. 2001), 1.35 µg-year/m3 (estimated range,
0–6.41 µg-year/m3) (Viet et al. 2000), and no
mean provided (estimated range, 0.9–41.2 µg-
year/m3) (Henneberger et al. 2001). An addi-
tional factor that probably contributes to the
higher prevalence of CBD in our cohort is the
long latency since last exposure, which would
have allowed a higher proportion of individuals
who were sensitized to progress on to CBD
than in other cohorts that have been studied
(Newman et al. 2005). Most previous preva-
lence studies of beryllium-exposed workers
have been of current employees (Henneberger
et al. 2001; Kelleher et al. 2001; Kreiss et al.
1996), or they have included former workers
(Stange et al. 2001) but have not presented
the results separately for current and former
workers. One study similar to ours only had
formerly exposed individuals (Kreiss et al.
1993b). This latter study, unlike ours, found
no individuals with sensitizations alone with-
out CBD. This would suggest that the higher
prevalence of CBD in our study population
was not solely related to the long latency since
last exposure because we would have expected
a lower rate of sensitization alone without
CBD if increased prevalence of CBD was
solely caused by the long latency.
Despite the fact that there is an overall
increase of beryllium disease in working popu-
lations with higher exposure to beryllium,
investigators have been unable to show a clear-
cut exposure response between air concentra-
tions of beryllium and CBD or sensitization
(Henneberger et al. 2001; Kelleher et al. 2001;
Viet et al. 2000). This has led researchers to
examine the possible role of particulate size
(Kelleher et al. 2001; McCawley et al. 2001)
and skin exposure (Tinkle et al. 2003).
We found no difference in duration of
exposure for individuals with CBD versus
those who had no evidence of beryllium dis-
ease, but we did ﬁnd that those who were sen-
sitized had begun work later, last worked
longer ago, and had a shorter duration of
exposure than did those with CBD or those
who tested normal (Table 7). This difference
for individuals with sensitization was also true
for cumulative and peak exposure (Table 8),
cumulative mixed and cumulative and mean
nonsoluble exposure (Table 9), cumulative
and mean dust, and cumulative mixed expo-
sure (Table 10). On the other hand, cumula-
tive and mean soluble and cumulative and
mean soluble fume exposures were lower for
CBD (Table 10).
In sum, we either found no exposure
response or the signiﬁcant exposure responses
we did ﬁnd were in the opposite direction than
expected, with individuals with CBD or sensiti-
zation having less estimated exposure than
those with no beryllium disease. The risk of
CBD compared with sensitization if a person’s
mean exposure was below the current DOE
(1999) permissible level of 0.2 µg/m3 was less
than if their mean level was > 0.2 µg/m3 but
below the current OSHA (2005) permissible
exposure level of 2 µg/m3 (Table 11). However,
only being exposed to beryllium less than either
the DOE or the OSHA time-weighted average
did not protect a worker from the development
of CBD or sensitization. There were only two
people in the cohort whose highest level of
exposure was never above the 0.2 µg/m3 DOE
standard. CBD and sensitization occurred even
if the highest level of exposure was never
greater than the 2 µg/m3 OSHA standard, and
our data would suggest that peak exposure lev-
els > 0.2 µg/m3 were as harmful as even higher
peak exposure levels > 2 µg/m3 (Table 12).
A possible explanation for the failure to
find an association between increased beryl-
lium disease and sensitization and increased
levels of exposure is that this analysis did not
consider the role of genetic predisposition to
both sensitization and disease. Because the
genetic marker glu69 on HLA-DPB1 has
been associated with 80–90% of cases of both
CBD and sensitization, a better control group
for this analysis would be HLA-DPB1 glu69–
positive individuals who did not have CBD or
sensitization. We have recently been funded to
test our population for this marker and thus
will eventually be able to determine the inter-
action of exposure and genetic predisposition.
The finding of higher working lifetime
beryllium exposures in those with CBD com-
pared with those who are just sensitized sug-
gests that the body burden of beryllium might
relate to the severity of disease in those with a
genetic predisposition. Our ﬁnding that sensi-
tized individuals compared with individuals
with CBD had a higher exposure to beryllium
in a soluble form and to fumes of beryllium
supports this hypothesis (in this facility soluble
beryllium and fume is practically equivalent,
r = 0.94). Presumably the soluble forms of
beryllium would be more likely to be mobilized
Rosenman et al.
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Table 9. Development of deﬁnite/probable CBD and sensitization by chemical form of beryllium, mixed, nonsoluble, and soluble: mean cumulative, mean average,
and mean peak exposure levels.
Mixed Nonsoluble Soluble
Cumulative Mean Peak Cumulative Mean Peak Cumulative Mean Peak
Disease outcome No. (µg-year/m3) (µg/m3) (µg/m3) (µg-year/m3) (µg/m3) (µg/m3) (µg-year/m3) (µg/m3) (µg/m3)
Deﬁnite/probable CBD 40 50 3.7 2.1 126 7.6 4.6 5.8a 0.8b 2.1
Sensitization 37 20c 2.3 4.4 61d 5.4e 2.8 19 2.3 4.4
Normal 377 49 3.4 3.5 128 7.4 4.5 26 1.6 3.6
ap < 0.0001 for deﬁnite/probable vs. normal. bp = 0.02 for deﬁnite/probable vs. normal. cp = 0.0005 for sensitization vs. normal. dp = 0.04 for sensitization vs. deﬁnite/probable, and p = 0.003
for sensitization vs. normal. ep = 0.02 for sensitization vs. normal.
Table 10. Development of definite/probable CBD and sensitization by physical form of beryllium, dust, fume, and mixed: mean cumulative, mean average, and
mean peak exposure levels.
Dust Fume Mixed
Cumulative Mean Peak Cumulative Mean Peak Cumulative Mean Peak
Disease outcome No. (µg-year/m3) (µg/m3) (µg/m3) (µg-year/m3) (µg/m3) (µg/m3) (µg-year/m3) (µg/m3) (µg/m3)
Deﬁnite/probable CBD 40 128 7.4 4.6 4a 0.7b 0.3 49 3.6 2.1
Sensitization 37 66c 5.1d 3.5 17 2.3 3.1 17e 2.4 4.4
Normal 377 138 7.1 5.4 20 1.4 1.3 46 3.3 3.5
ap = 0.0002 for deﬁnite/probable vs. normal. bp = 0.03 for deﬁnite/probable vs. normal. cp = 0.0021 for sensitization vs. normal. dp = 0.009 for sensitization vs. normal. ep = 0.0004 for sensitization
vs. normal.and eliminated and result in a lower body bur-
den of beryllium compared with a similar expo-
sure to insoluble beryllium.
Individuals who have recently converted
their PPD (puriﬁed protein derivative) skin test
for tuberculosis to positive may, after treat-
ment, revert to a negative PPD (Tager et al.
1985). Thus, with decreasing or elimination of
the antigen, the cellular immune response (i.e.,
PPD reaction) may fade or be eliminated.
Because the PPD reaction is similar to BeLPT,
this suggests that a decreased immune response
to beryllium may occur in individuals with a
lower body burden of beryllium (i.e., antigen).
Thus, a reduced immune response to beryl-
lium may account for the association of beryl-
lium sensitization with a lower body burden of
insoluble beryllium or predominantly soluble
beryllium exposure compared with individuals
with CBD. An alternative explanation that less
soluble beryllium exposure is confounded by
elevated levels of other forms of beryllium is
not supported by analyzing potential correla-
tions between levels of exposures to the differ-
ent forms of beryllium.
Other researchers have suggested the
importance of skin exposures to the develop-
ment of beryllium disease. We have no data
to directly address whether skin exposure is of
importance in the development of beryllium
disease in this cohort. However, others have
hypothesized that small particle size increases
the likelihood of both inhalation and skin
absorption and exposure (McCawley et al.
2001). Our data showed the opposite results
with reduced levels of exposure to fume,
which would be the smallest particle size form
of exposure that occurred in this facility, and
CBD (Table 10).
A limitation of our study is the uncertainty
in the exposure estimates. The exposure metrics
developed for study participants were based on
relatively sparse data, with interpolation from
measurement data for years when no data were
available. Major gaps in the data were associated
with the mid-1960s and from 1977 to 1981.
Exposure estimates for the earlier time period
were based on measurements in preceding or
succeeding years; for the later time period, esti-
mates for the mid-1970s were extended into
the later years. These decisions were based on
plant history and conversations with long-term
workers. All interpolation was accomplished
using preestablished rules and was independent
of any knowledge of disease status. The use of
professional judgment like this is often required
in retrospective exposure assessment studies.
Because the exposure estimates were created for
jobs and tasks, without knowledge of a work
history or disease status, it is likely that this mis-
classiﬁcation would be nondifferential, attenu-
ating any ability to detect exposure–response
relations (Checkoway et al. 1991; Copeland
et al. 1977).
A further limitation relates to the effect of
nonparticipants on study results. The overall
participation rate was high and nonparticipants
were generally similar to participants except
their duration of exposure was less. However, it
is possible that the 11% of the total cohort that
did not participate had a lower rate of CBD
because asymptomatic individuals might be
less motivated to participate. On the other
hand, the 24% of the cohort who were
deceased at the initiation of our study and the
11% we could not locate might be expected to
have a higher prevalence of disease.
A third limitation of our study is that we
used a single laboratory for the blood lympho-
cyte testing for beryllium in a one-time screen-
ing. It has recently been reported that the use
of a single laboratory results in false negative
results of 20–30% (Stange et al. 2004).
Because radiographs were part of our screen-
ing, we would expect the false negative rate for
CBD to be lower than the potential false nega-
tive rate for sensitization. Because our cohort
was no longer exposed to beryllium, it is less
likely that repeat screening will identify addi-
tional cases of CBD or sensitization, as has
been shown in currently exposed cohorts
(Newman et al. 2001).
The participation level of individuals who
warranted more extensive testing after the
initial screening is another limitation of this
study. Only 56 of the 110 (51%) individuals
who screened positive by radiograph or BeLPT
elected to have a bronchoscopy. Participation
in more extensive testing was similar in those
with positive radiographs (47%) and those
with abnormal positive BeLPT only (57%).
The lack of a biopsy and broncholavage in half
of the individuals who were positive on the
initial medical screening means we may have
misclassified individuals into the definite/
probable CBD and sensitization groups. This
misclassiﬁcation would decrease the likelihood
of ﬁnding an exposure–response or other rela-
tionship with CBD or sensitization. To mini-
mize misclassiﬁcation errors, we excluded cases
classiﬁed as possible CBD or possible sensitiza-
tion from both the disease and normal groups
during analysis. However, we included four
individuals classified as CBD because of a
diagnosis at the University of Pennsylvania
before our study, although these individuals
never had evidence of sensitization in their
bronchial lavage fluid or blood. We are not
aware of any reason how misclassification
could cause the inverse relationship between
exposure and disease that we found.
A final limitation is that multiple com-
parisons were made in Tables 9 and 10.
Adjustments for these multiple comparisons
can be made by tripling the p-value reported,
using the properties of the Bonferroni
inequality. If this were done, a number of the
associations would no longer be statistically
significant in Tables 9 and 10. Given the
consistent direction of the ﬁndings, our con-
clusions concerning soluble and nonsoluble
forms of beryllium remain unchanged even if
this adjustment were made.
In conclusion, this cohort is a high-risk
group for the development of CBD and sensi-
tization. The development of beryllium dis-
ease has continued to occur years after
exposure has ceased. Former beryllium work-
ers and their health care providers need to be
aware of this ongoing risk. A combination of
two positive BeLPTs and an abnormal chest
radiograph on the initial medical screening
was the best predictor of the presence of CBD.
However, there were individuals who had
CBD with an abnormal chest radiograph,
involving all or just the upper lobes, and nega-
tive BeLPT (Table 6).
We were unable to show an exposure–
response relationship. The inclusion of genetic
data combined with exposure data may better
deﬁne which individuals in this cohort are at a
particularly high risk of development of CBD
and/or sensitization and may account for the
absence of the typical exposure–response seen
with other environmental or occupational
toxins. We are currently performing molecular
typing of DRB1 and DPB1 alleles on individ-
uals with CBD and sensitization and a sample
of those who tested normal to investigate for a
possible gene–exposure relationship.
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Table 11. Development of definite/probable CBD and sensitization by the American Conference of
Governmental and Industrial Hygienists notice of intended change, current OSHA, and DOE DWA threshold
levels.
Mean DWA exposure (µg/m3) [n (%)]
Disease outcome 0 to < 0.02 0.02 to < 0.2 0.2 to < 2 ≥ 2
Deﬁnite/probable CBD 1 (7) 0 (0) 4 (17) 35 (8)
Sensitization 2 (14) 0 (0) 2 (8) 33 (8)
Normal 11 (79) 0 (0) 18 (75) 348 (84)
Table 12. Development of deﬁnite/probable CBD and sensitization by highest exposure.
Highest exposure level (µg/m3) [n (%)]
Disease outcome 0 to < 0.2 0.2 to < 2 ≥ 2
Deﬁnite/probable CBD 0 (—) 18 (9.3) 22 (8.5)
Sensitization 0 (—) 19 (9.8) 18 (7.0)
Normal 2 (100) 157 (80.9) 218 (84.5)Rosenman et al.
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This cohort is a high-risk group for the
development of CBD and sensitization. The
development of beryllium disease has contin-
ued to occur years after exposure has ceased.
Former beryllium workers and their health
care providers must be kept aware of this
ongoing risk.
The results of this study show that current
occupational health standards for beryllium
do not provide adequate protection against
the development of CBD or sensitization.
Twenty-four percent of the workforce that
was exposed to beryllium below the current
OSHA (2005) allowable threshold limit value
developed CBD or sensitization. Similar levels
of adverse outcomes (21%) were seen in those
exposed to beryllium below the time-
weighted average DOE (1999) guideline of
0.2 µg/m3. Even the more protective time-
weighted average of 0.02 µg/m3 proposed by
the American Conference of Governmental
and Industrial Hygienists (2005) did not
eliminate adverse outcomes. The identifica-
tion of cases of CBD and sensitization in this
population at levels of cumulative exposure
lower than current standards or guidelines
underscores the need to more fully under-
stand the determinants of exposure (e.g.,
peak, physical/chemical form) that may con-
tribute to disease risk, so that these may be
included in standard setting.
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